HAE vs. MMSI, ICUI, IRTC, AXNX, PRCT, IART, TNDM, NARI, ATEC, and GMED
Should you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include Merit Medical Systems (MMSI), ICU Medical (ICUI), iRhythm Technologies (IRTC), Axonics (AXNX), PROCEPT BioRobotics (PRCT), Integra LifeSciences (IART), Tandem Diabetes Care (TNDM), Inari Medical (NARI), Alphatec (ATEC), and Globus Medical (GMED). These companies are all part of the "surgical & medical instruments" industry.
Merit Medical Systems (NASDAQ:MMSI) and Haemonetics (NYSE:HAE) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
Merit Medical Systems has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500.
Haemonetics has lower revenue, but higher earnings than Merit Medical Systems. Haemonetics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.
In the previous week, Merit Medical Systems had 2 more articles in the media than Haemonetics. MarketBeat recorded 9 mentions for Merit Medical Systems and 7 mentions for Haemonetics. Haemonetics' average media sentiment score of 1.14 beat Merit Medical Systems' score of 1.01 indicating that Merit Medical Systems is being referred to more favorably in the media.
Merit Medical Systems presently has a consensus price target of $92.50, indicating a potential upside of 26.06%. Haemonetics has a consensus price target of $104.67, indicating a potential upside of 19.41%. Given Haemonetics' stronger consensus rating and higher possible upside, analysts plainly believe Merit Medical Systems is more favorable than Haemonetics.
99.7% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 3.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 1.8% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Haemonetics has a net margin of 9.97% compared to Haemonetics' net margin of 7.51%. Merit Medical Systems' return on equity of 22.37% beat Haemonetics' return on equity.
Merit Medical Systems received 26 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 68.63% of users gave Merit Medical Systems an outperform vote while only 60.86% of users gave Haemonetics an outperform vote.
Summary
Merit Medical Systems beats Haemonetics on 11 of the 18 factors compared between the two stocks.
Get Haemonetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Haemonetics Competitors List
Related Companies and Tools
